Paul Tardi

USPTO Granted Patents = 16 (Patent Applications = 11)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 346(Granted Patents)

Location History:

Princeton, NJ (US) (2013)
Surrey, CA (2007 - 2023)

Company Filing History:

15 out of 25

Celator Pharmaceuticals, Inc.

patents

2 out of 504

Oregon Health & Science University

patents

1 out of 1

Jazz Pharmaceuticals Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12447163 - Liposomal formulations of Bcl inhibitors (2025-10-21),

2. 11746386 - Assays and methods for selecting a treatment regimen for a subject with leukemia (2023-09-05),

3. 11413253 - Nanoparticle delivery systems (2022-08-16),

4. 10927418 - Assays and methods for selecting a treatment regimen for a subject with leukemia (2021-02-23),

5. 10835492 - Method of lyophilizing liposomes (2020-11-17),

6. 10722464 - Compositions for delivery of drug combinations (2020-07-28),

7. 10285951 - Nanoparticle delivery systems (2019-05-14),

8. 10166184 - Method of lyophilizing liposomes (2019-01-01),

9. 10058507 - Compositions for delivery of drug combinations (2018-08-28),

10. 10028912 - Method of lyophilizing liposomes (2018-07-24),

11. 9271931 - Compositions for delivery of drug combinations (2016-03-01),

12. 8518437 - Lipid carrier compositions with enhanced blood stability (2013-08-27),

13. 8486924 - Taxane delivery system (2013-07-16),

14. 7850990 - Compositions for delivery of drug combinations (2010-12-14),

15. 7744921 - Liposome loading with metal ions (2010-06-29),

Title: Paul Tardi: Innovator in Cancer Treatment Technologies

Introduction: Paul Tardi is a leading inventor specializing in innovative therapies for cancer treatment, based in Surrey, Canada. With a portfolio of 15 patents, his work has significantly advanced the field of oncology, focusing on improving therapeutic outcomes for patients with leukemia and other types of cancer.

Latest Patents: Tardi's most notable recent patents include groundbreaking methods and assays aimed at optimizing treatment regimens for individuals afflicted with leukemia. His diagnostic methods enhance the identification of cancer-bearing subjects suitable for treatment with CPX-351 through genetic evaluations and ex vivo testing of patient cells. Additionally, he has developed nanoparticle delivery systems that combine prodrugs with therapeutic agents, yielding enhanced therapeutic effects compared to traditional free forms of these drugs.

Career Highlights: Paul Tardi has made substantial contributions to the pharmaceutical industry, particularly through his roles at Celator Pharmaceuticals, Inc. and Oregon Health & Science University. His research has not only propelled advancements in cancer therapies but has also paved the way for future research in related fields.

Collaborations: Throughout his career, Tardi has collaborated with esteemed colleagues, including Lawrence D. Mayer and Murray Webb. These partnerships have facilitated the exchange of ideas and contributed to the development of innovative solutions in cancer treatment.

Conclusion: Paul Tardi's commitment to innovation in cancer therapeutics is evident through his numerous patents and collaborative efforts. His work exemplifies the critical intersection of research and practical application in medicine, offering hope for improved treatment strategies in oncology.

This text is generated by artificial intelligence and may not be accurate.